Treatment patterns and survival outcomes for small-cell lung cancer patients – a Swedish single center cohort study

References

• Rossi A, Martelli O, Di Maio M. Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. Cancer Treatment Rev. 2013;39(5):498–506.
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229.
   PubMed Web of Science ®Google Scholar
• Naito Y, Yamada K, Imamura Y, et al. Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer. Med Oncol. 2018;35(5):61.
   PubMed Web of Science ®Google Scholar
• Shiozawa T, Sekine I, Aida Y, et al. Rechallenge with first-line platinum chemotherapy for sensitive-relapsed small-cell lung cancer. Case Rep Oncol. 2018;11(3):622–632.
   PubMed Web of Science ®Google Scholar
• Genestreti G, Tiseo M, Kenmotsu H, et al. Outcomes of platinum-sensitive small-cell lung cancer patients treated with platinum/etoposide rechallenge: a multi-institutional retrospective analysis. Clin Lung Cancer. 2015;16(6):e223–e228.
   PubMed Web of Science ®Google Scholar
• von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658–667.
   PubMed Web of Science ®Google Scholar
• O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24(34):5441–5447.
   PubMed Web of Science ®Google Scholar
• Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25(15):2086–2092.
   PubMed Web of Science ®Google Scholar
• Oronsky B, Reid TR, Oronsky A, et al. What's new in SCLC? A review. Neoplasia (New York, NY). 2017;19(10):842–847.
   PubMed Web of Science ®Google Scholar
• Ready N, Farago AF, de Braud F, et al. Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol. 2019;14(2):237–244.
   PubMed Web of Science ®Google Scholar
• Aupérin A, Arriagada R, Pignon J-P, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 1999;341(7):476–484.
   PubMed Web of Science ®Google Scholar
• Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357(7):664–672.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(5):663–671.
   PubMed Web of Science ®Google Scholar
• National Guidelines Sweden, Small Cell Lung Cancer; 2018. [cited 2020 Jan 2]. Available from: https://www.cancercentrum.se/samverkan/cancerdiagnoser/lunga-och-lungsack/vardprogram/
   Google Scholar
• NGS SCLC. [cited 2020 Jan 2]. Available from: https://www.cancercentrum.se/samverkan/cancerdiagnoser/lunga-och-lungsack/vardprogram/
   Google Scholar
• Coutinho AD, Shah M, Lunacsek OE, et al. Real-world treatment patterns and outcomes of patients with small cell lung cancer progressing after 2 lines of therapy. Lung Cancer. 2019;127:53–58.
   PubMed Web of Science ®Google Scholar
• Steffens CC, Elender C, Hutzschenreuter U, et al. Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study. Lung Cancer. 2019;130:216–225.
   PubMed Web of Science ®Google Scholar
• Tendler S, Grozman V, Lewensohn R, et al. Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden. Lung Cancer (Amsterdam, Netherlands). 2018;120:75–81.
   PubMed Web of Science ®Google Scholar
• Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer – what limits limited disease? Lung Cancer. 2002;37(3):271–276.
   PubMed Web of Science ®Google Scholar
• Bernhardt D, Aufderstrasse S, Konig L, et al. Impact of inflammatory markers on survival in patients with limited disease small-cell lung cancer undergoing chemoradiotherapy. Cancer Manag Res. 2018;10:6563–6569.
   PubMed Web of Science ®Google Scholar
• Anami S, Doi H, Nakamatsu K, et al. Serum lactate dehydrogenase predicts survival in small-cell lung cancer patients with brain metastases that were treated with whole-brain radiotherapy. J Radiat Res. 2018;60(2):257–263.
   Web of Science ®Google Scholar
• Jager KJ, van Dijk PC, Zoccali C, et al. The analysis of survival data: the Kaplan–Meier method. Kidney Int. 2008;74(5):560–565.
   PubMed Web of Science ®Google Scholar
• Pietanza MC, Byers LA, Minna JD, et al. Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res. 2015;21(10):2244–2255.
   PubMed Web of Science ®Google Scholar
• Garassino MC, Torri V, Michetti G, et al. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer. 2011;72(3):378–383.
   PubMed Web of Science ®Google Scholar
• Jones GS, McKeever TM, Hubbard RB, et al. Factors influencing treatment selection and 30-day mortality after chemotherapy for people with small-cell lung cancer: an analysis of national audit data. Eur J Cancer. 2018;103:176–183.
   PubMed Web of Science ®Google Scholar
• Kim YH, Mishima M. Second-line chemotherapy for small-cell lung cancer (SCLC). Cancer Treat Rev. 2011;37(2):143–150.
   PubMed Web of Science ®Google Scholar
• Zhang X, Guo M, Fan J, et al. Prognostic significance of serum LDH in small cell lung cancer: a systematic review with meta-analysis. Cancer Biomark. 2016;16(3):415–423.
   PubMed Web of Science ®Google Scholar
• Meert AP, Paesmans M, Berghmans T, et al. Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer. 2001;1(1):5.
   PubMed Web of Science ®Google Scholar
• Gaspar LE, Gay EG, Crawford J, et al. Limited-stage small-cell lung cancer (stages I–III): observations from the National Cancer Data Base. Clin Lung Cancer. 2005;6(6):355–360.
   PubMedGoogle Scholar
• Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3):324s–339s.
   PubMed Web of Science ®Google Scholar
• Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017;18(8):1116–1125.
   PubMed Web of Science ®Google Scholar
• Rossi A, Sacco PC, Sgambato A, et al. Optimal drugs for second-line treatment of patients with small-cell lung cancer. Expert Opin Pharmacother. 2016;17(7):969–976.
   PubMed Web of Science ®Google Scholar
• Huang R, Wei Y, Hung RJ, et al. Associated links among smoking, chronic obstructive pulmonary disease, and small cell lung cancer: a pooled analysis in the International Lung Cancer Consortium. EBioMedicine. 2015;2(11):1677–1685.
   PubMed Web of Science ®Google Scholar